This Website uses cookies which are essential for providing our services and core website functionality. In addition, if you click on "I AGREE", we will further use analytical and advertising cookies to analyse your use of our Website so that we can improve its functionality and display content tailored according to your interests and preferences, including on third party websites. We use Google Analytics and its tracking and remarketing features connected with Google Ads. This means that cookies on your device will be placed and accessed by Google LLC in the USA enabling us and third parties participating in the Google advertising network to conduct conversion tracking and remarketing activities across different websites and devices. By accepting analytical and advertising cookies you consent to the respective processing and sharing of your personal data with Google LLC. You can withdraw your consent and change your cookie preferences at any time by using our Cookie preferences tool . To refuse consent and continue without analytical and advertising cookies, please click on "I DO NOT AGREE". For more information see our cookie policy .

Engagiert in der Forschung. Im Einsatz für den Patienten. Daiichi Sankyo Deutschland GmbH

Engagiert in der Forschung. Im Einsatz für den Patienten.

Daiichi Sankyo Deutschland GmbH

Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)

Die Pressemeldungen in englischer Sprache finden Sie hier

Zurück